Product category:
Calibration and Laboratory Instruments
News Release from: LGC
Edited by the Manufacturingtalk Editorial
Team on 03 July 2003
Pharmacogenetic Licensing Continues To
Expand
LGC, the UK's leading independent analytical laboratory, has granted its fifth non-exclusive licence in a year for the gene variant CYP2D6*4 involved in drug metabolism.
LGC, the UK's leading independent analytical laboratory, has granted its fifth non-exclusive licence in a year for the gene variant CYP2D6*4 involved in drug metabolism The latest licence issued to EPIDAUROS Biotechnologie AG is the second to a German-based company following last year's agreement with GeneScan in November 2002
This article was originally published on Manufacturingtalk on 10 Mar 2003 at 8.00am (UK)
Related stories
LGC Launches ADME-Tox Screening Service
Bioanalytical services at LGC's new ADME-Tox laboratory include in vitro drug metabolism, cellular toxicology and prediction of gastrointestinal transport.
Phytochemical Reference Standards Now Available
Over 2500 high purity ChromaDex phytochemical - or herbal - reference standards are now available exclusively from LGC Promochem throughout Europe.
Earlier this year, a licence was issued to Tm Bioscience, a Canadian DNA-based diagnostics company.
Suzanne Smith, Group Legal Adviser and Company Secretary at LGC said: "LGC is delighted to have issued this latest licence to EPIDAUROS Biotechnologie AG.
There is tremendous growth in this sector with several companies beginning to offer pharmacogenetic services and products, especially those which include CYP2D6*4.
LGC is licensing the leading providers of genotyping services, testing kits and bio-chip manufacturers as well as pharmaceutical and biotech companies worldwide.
We are also able to license companies providing in-house testing." Dr Paul Debenham, Director of Life Sciences at LGC, said: "Now that it is possible to take into account how individuals differ in their ability to respond to various prescribed medications, the concept of personalised medicine is internationally accepted as the way forward to avoid serious adverse drug reactions.
Interest in this field is rapidly growing and LGC is experiencing a significant number of enquiries from companies in the drug discovery and pharmaceutical sectors in CYP2D6*4 test.
We are therefore particularly pleased to be able to make this technology available under licence on a worldwide scale or through a CYP2D6*4 testing service at LGC in the UK." LGC's first non-exclusive CYP2D6*4 licence was issued to Orchid BioSciences Inc in June 2002 for North America, closely followed by another to a European company.
LGC is currently in discussions with other companies as its licensing business continues to expand.
• LGC: contact details and other news
• Email this article to a colleague
• Register for the free Manufacturingtalk email newsletter
• Manufacturingtalk Home Page
Search the Pro-Talk network of sites
